相关实验视频
Updated: Jun 13, 2025

09:32
Differentiation of Mouse Breast Epithelial HC11 and EpH4 Cells
Published on: February 27, 2020
8.8K
揭示了类效应:在癌细胞分化中的PPARγ激活剂和MEK抑制剂
Rakefet Ben-Yishay1, Opher Globus1, Nora Balint-Lahat2
1Oncology Institute, Sheba Medical Center, Ramat Gan 5262000, Israel.
Cells
|September 14, 2024
概括
这项研究表明,结合PPARγ激动剂和MEK抑制剂可以成功将侵袭性乳腺癌细胞分化为脂肪细胞,为侵袭性乳腺癌亚型提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 皮质转介质转变 (EMT) 驱动乳腺癌的进展和耐药性.
- 不分化的癌细胞表现出可塑性,导致具有侵略性的表型.
- 准癌细胞的可塑性提供了一个新的治疗途径.
研究的目的:
- 为了研究侵入性乳腺癌细胞的跨差异化治疗方法.
- 评估PPARγ激动剂和MEK抑制剂在诱导癌细胞分化中的有效性.
- 探索组合疗法,以克服侵袭性乳腺癌的耐药性.
主要方法:
- 利用小鼠乳腺癌细胞和患者衍生转移的活体培养.
- 使用PPARγ激动剂 (罗西格利塔,皮奥格利塔) 和MEK抑制剂 (科比米提尼布).
- 评估的脂肪生成标志物:PPARγ和C/EBPα上调,细胞骨重组,脂质滴积累.
主要成果:
- PPARγ 主动剂和MEK 抑制剂诱导癌细胞转基因分化为脂肪细胞.
- 罗西格利塔和皮奥格利塔促进了脂肪生成,由分子和形态变化证实.
- 与TGFβ结合使用的科比美提尼布显示出显著的亲基效应.
- 与Pioglitazone和Cobimetinib在三阴性乳腺癌细胞中观察到的协同PPARγ上调.
结论:
- PPARγ激动剂和MEK抑制剂的组合代表了对侵袭性乳腺癌的有前途的治疗策略.
- 针对癌细胞的可塑性和脱差,可以克服药物耐药性.
- 差异化治疗有可能用于治疗侵袭性和转移性乳腺癌亚型.
相关概念视频
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K

